News

The single-arm Phase II trial evaluated a 1800mg/m2 dose of ASA404 in combination with carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer. Median survival was

According to Ovation, in previous studies, clobazam was shown to be well tolerated in patients with Lennox-Gastaut syndrome (LGS). The treatment met the primary endpoint in a Phase

<p>The new formulation, using Eurand&#0039;s Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth without leaving a sour or bitter taste. Eurand could potentially receive

Sular is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented Geomatrix technology, which is designed to provide

The FDA has also granted GTC permission to submit the associated biologics license application, or BLA, for ATryn on a rolling basis. Fast Track status speeds up the

Biovail Pharmaceuticals Canada (BPC), Biovail’s Canadian sales and marketing division, will introduce the features and benefits of Ralivia to health-care professionals throughout Canada. BPC anticipates launching Ralivia shortly.

The randomized, double-blind, placebo-controlled study of 410 adult patients with major depressive disorder achieved the primary endpoint of mean change from baseline in the Montgomery-Asberg Depression Rating Scale

The Phase I component enrolled patients at three centers in Canada and is evaluating the safety and feasibility of administrating nimotuzumab, a humanized monoclonal antibody that targets the

During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is